Skip to content

Novosyn® Quick in Patients Undergoing Episiotomy Closure

Observational, Retrospective, Monocentric Clinical Study on the Safety of Novosyn® Quick in Women With a Spontaneous Vaginal Delivery Who Required an Indicated Episiotomy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05233527
Acronym
RETRO-EPINOQ
Enrollment
229
Registered
2022-02-10
Start date
2024-05-09
Completion date
2026-10-01
Last updated
2026-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Episiotomy Wound

Brief summary

Retrospective, monocentric clinical study on the clinical performance of Novosyn® Quick in patients undergoing episiotomy closure.

Detailed description

The study design is a retrospective, consecutive series of women with a spontaneous vaginal delivery who required an indicated episiotomy with Novosyn® Quick between the period January 2020 - December 2020 at Hospital General de Catalunya. All women treated with Novosyn® Quick between January 2020 - December 2020 at the Hospital General de Catalunya will be analyzed. The investigator team will access medical records for the cohort of patients identified.

Interventions

PROCEDUREEpisiotomy Closure

indicated episiotomy with Novosyn® Quick after spontaneous vaginal delivery

Sponsors

Aesculap AG
Lead SponsorINDUSTRY
B.Braun Surgical SA
CollaboratorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women who underwent an indicated episiotomy between January 2020 - December 2020 at the Hospital General de Catalunya (Sant Cugat del Vallès, Spain) and received Novosyn® Quick

Exclusion criteria

* No

Design outcomes

Primary

MeasureTime frameDescription
Wound dehiscence rateup to 1 month postpartumA dehiscence of the wound which needs surgical treatment with re-closure.

Secondary

MeasureTime frameDescription
Rate of Re-suturingup to 1 month postpartumNumber of patients requiring a re-suturing due to wound dehiscence
Rate of Suture removal due to wound problemsup to 1 month postpartumNumber of patients requiring suture removal due to wound problems (infection, gaping wound, residual material requiring removal)
Surgical Site Infection rateup to 1 month postpartumA surgical site infection is an infection that occurs after surgery in the part of the body where the surgery took place. Surgical site infections can sometimes be superficial infections (A1) involving the skin only. Other surgical site infections are more serious and can involve tissues under the skin, organs, or implanted material (A2).
Bleedingup to 1 month postpartumIncidence of Bleeding after Episiotomy closure
Hematomaup to 1 month postpartumIncidence of Hematoma after Episiotomy closure
Abscess formationup to 1 month postpartumIncidence of Abscess formation after Episiotomy closure
Rectovaginal fistulaup to 1 month postpartumIncidence of Rectovaginal fistula after Episiotomy closure
Short-term perineal pain (VAS)after 48 hours postpartumThis parameter will be noted using the Visual Analogue Scale (VAS) which state "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain".
Long-term perineal pain (VAS)up to 1 month postpartumThis parameter will be noted using the Visual Analogue Scale (VAS) which state "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain".
Short-term Pain in daily living (VAS)24-48 hours postpartumThis parameter will be noted using the Visual Analogue Scale (VAS) which state "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain".in repose, during walking, during sitting, when urinating, and when defecating
Long-term Pain in daily living (VAS)up to 1 month postpartumThis parameter will be noted using the Visual Analogue Scale (VAS) which state "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain".in repose, during walking, during sitting, when urinating, and when defecating

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 18, 2026